- Home
- CMPS vs ANAB Comparison
CMPS vs ANAB Comparison
Compare CMPS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | ANAB |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United Kingdom | United States |
| Employees | 156 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMPS | ANAB |
|---|---|---|
| Price | $13.39 | $58.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $25.38 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 3.5M | 575.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $3.97 | $17.11 |
| 52 Week High | $15.40 | $73.30 |
Technical Indicators
Market Signals| Indicator | CMPS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 52.88 |
| Support Level | $10.66 | $50.74 |
| Resistance Level | $14.92 | $68.22 |
| Average True Range (ATR) | 0.75 | 2.49 |
| MACD | 0.19 | 0.57 |
| Stochastic Oscillator | 67.62 | 85.87 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).